08-13 Evotec's final first-half results once again spook investors DP
08-13 Evotec SE Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-13 Evotec SE : Gets a Buy rating from RBC ZD
08-13 Evotec : Half-year report 2026, PDF (H1 Report 2026 English) PU
08-13 Evotec : Half-year report 2026, PDF (Interim Statement H1 2026 English) PU
08-13 Evotec Se Announces Camilla Macapili Languille Step Down as Supervisory Board, Effective August 7, 2026 CI
08-13 Evotec Se Reaffirms Earnings Guidance for the Full-Year 2026 CI
08-06 Evotec, Odyssey Therapeutics Partner to Develop Autoimmune, Inflammatory Disease Treatments MT
08-06 Evotec, Odyssey Therapeutics Team Up on Autoimmune, Inflammatory Disease Treatment Research MT
08-06 Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases EQ
08-06 Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PU
08-03 Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 CI
08-03 Niagen Bioscience, Evotec to Advance Preclinical Development of NB4168 MT
07-16 Berenberg Downgrades Evotec to Hold From Buy, Cuts Price Target to EUR3.60 From EUR9.40 MT
07-16 EVOTEC : Deutsche Bank reaffirms its Neutral rating ZD
07-16 EVOTEC : Reduced to Neutral by Berenberg ZD
07-16 Berenberg downgrades Evotec to 'Hold', target cut to €3.60 DP
07-15 Evotec Shares Fall After TD Cowen Downgrade MT
07-15 TD Cowen Downgrades Evotec to Hold From Buy, Adjusts Price Target to $2 From $4 MT
07-14 Evotec SE, Q2 2026 Earnings Call, Jul 14, 2026
07-14 Evotec plunges after profit warning to lowest share price in ten years DP
07-14 EVOTEC : Deutsche Bank reaffirms its Neutral rating ZD
07-14 Evotec abandons profit hopes, shares slide DP
07-14 EVOTEC : RBC gives a Buy rating ZD
07-14 Evotec at risk of lowest share price in ten years after profit warning DP
No results match your criteria